Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

[Autism and attention deficit hyperactivity disorder: pharmacological intervention].

Fernández-Jaén A, Martín Fernández-Mayoralas D, Fernández-Perrone AL, Calleja-Pérez B, Muñoz-Jareño N, López-Arribas S.

Rev Neurol. 2013 Sep 6;57 Suppl 1:S205-10. Review. Spanish.

2.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
3.
5.

Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.

Schulz KP, Fan J, Bédard AC, Clerkin SM, Ivanov I, Tang CY, Halperin JM, Newcorn JH.

Arch Gen Psychiatry. 2012 Sep;69(9):952-61. doi: 10.1001/archgenpsychiatry.2011.2053.

PMID:
22945622
6.

A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.

Harfterkamp M, van de Loo-Neus G, Minderaa RB, van der Gaag RJ, Escobar R, Schacht A, Pamulapati S, Buitelaar JK, Hoekstra PJ.

J Am Acad Child Adolesc Psychiatry. 2012 Jul;51(7):733-41. doi: 10.1016/j.jaac.2012.04.011. Epub 2012 May 25.

PMID:
22721596
7.

[Autism and ADHD across the life span. Differential diagnoses or comorbidity?].

Banaschewski T, Poustka L, Holtmann M.

Nervenarzt. 2011 May;82(5):573-80. doi: 10.1007/s00115-010-3239-6. Review. German.

PMID:
21484168
8.

Attention-deficit-hyperactivity disorder: an update.

Dopheide JA, Pliszka SR.

Pharmacotherapy. 2009 Jun;29(6):656-79. doi: 10.1592/phco.29.6.656. Review.

PMID:
19476419
9.

Pharmacological treatment of attention-deficit/hyperactivity disorder in adults.

Slatkoff J, Greenfield B.

Expert Opin Investig Drugs. 2006 Jun;15(6):649-67. Review.

PMID:
16732717
10.

Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders.

Pringsheim T, Steeves T.

Cochrane Database Syst Rev. 2011 Apr 13;(4):CD007990. doi: 10.1002/14651858.CD007990.pub2. Review.

PMID:
21491404
11.

Methylphenidate an effective treatment for ADHD?

McDougle CJ.

J Autism Dev Disord. 2004 Oct;34(5):593-4. No abstract available.

PMID:
15628613
13.

Attention-deficit/Hyperactivity Disorder in the context of Autism spectrum disorders.

Murray MJ.

Curr Psychiatry Rep. 2010 Oct;12(5):382-8. doi: 10.1007/s11920-010-0145-3. Review.

PMID:
20694583
14.

Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.

Kaplan G, Newcorn JH.

Pediatr Clin North Am. 2011 Feb;58(1):99-120, xi. doi: 10.1016/j.pcl.2010.10.009. Review.

PMID:
21281851
15.

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

Gibson AP, Bettinger TL, Patel NC, Crismon ML.

Ann Pharmacother. 2006 Jun;40(6):1134-42. Epub 2006 May 30. Review.

PMID:
16735655
16.

Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.

[No authors listed]

Prescrire Int. 2010 Feb;19(105):5-8.

PMID:
20455329
17.

Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?

Niederhofer H.

Psychiatr Danub. 2009 Sep;21(3):330. No abstract available.

18.

Improving decision making in the treatment of ADHD.

Vitiello B.

Am J Psychiatry. 2008 Jun;165(6):666-7. doi: 10.1176/appi.ajp.2008.08030365. No abstract available.

PMID:
18519529
19.

Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.

Huang YS, Tsai MH.

CNS Drugs. 2011 Jul;25(7):539-54. doi: 10.2165/11589380-000000000-00000. Review. Erratum in: CNS Drugs. 2011 Nov 1;25(11):932. Dosage error in article text.

PMID:
21699268
20.

Methylphenidate vs atomoxetine: personalized medicine in attention- deficit/hyperactivity disorder.

Heinrich H, Studer P, Moll GH, Kratz O.

JAMA Psychiatry. 2013 May;70(5):545. doi: 10.1001/jamapsychiatry.2013.760. No abstract available.

PMID:
23636880

Supplemental Content

Support Center